Immunoprecise Antibodies Ltd Stock Other OTC
Stocks
CA87588T1030
Pharmaceuticals
| Market Cap | 111M 79.53M 69.02M 63.62M 59.61M 7.62B 114M 759M 294M 3.67B 299M 292M 12.76B | P/E Ratio 2026 * |
-7.19x | P/E Ratio 2027 * | -8.63x |
|---|---|---|---|---|---|
| Enterprise Value | 111M 79.53M 69.02M 63.62M 59.61M 7.62B 114M 759M 294M 3.67B 299M 292M 12.76B | EV / Sales 2026 * |
7.02x | EV / Sales 2027 * | 5.44x |
| Free-Float |
90.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Immunoprecise Antibodies Ltd
| 1 day | -6.29% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 57 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.29% | -23.22% | - | - | 79.96M | |
| +2.25% | -2.32% | +18.42% | -18.55% | 61.21B | |
| +2.50% | +4.43% | +64.44% | +218.90% | 58.15B | |
| -0.92% | +28.60% | +28.60% | +28.60% | 39.54B | |
| +4.16% | +16.25% | -56.08% | -64.88% | 35.08B | |
| +3.00% | +1.70% | +50.15% | -36.25% | 28.68B | |
| +3.10% | +7.33% | +57.83% | +74.98% | 21.06B | |
| +7.12% | -5.19% | +76.25% | -60.40% | 18.25B | |
| -1.88% | -5.07% | -10.05% | +93.76% | 16.49B | |
| +0.78% | -1.57% | +44.59% | +101.10% | 15.87B | |
| Average | +1.37% | +1.25% | +30.46% | +37.47% | 32.7B | |
| Weighted average by Cap. | +2.22% | +1.44% | +29.31% | +44.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.88M 11.34M 9.84M 9.07M 8.5M 1.09B 16.21M 108M 41.88M 523M 42.56M 41.64M 1.82B | 20.47M 14.62M 12.68M 11.69M 10.96M 1.4B 20.9M 139M 54M 675M 54.87M 53.69M 2.35B |
| Net income | -14.29M -10.2M -8.85M -8.16M -7.65M -977M -14.59M -97.36M -37.7M -471M -38.3M -37.48M -1.64B | -12M -8.57M -7.44M -6.86M -6.42M -821M -12.25M -81.79M -31.66M -396M -32.18M -31.48M -1.38B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
